Shire to buy FerroKin for up to $325m bringing in iron chelator candidate

Shire is buying privately-held US biotech company FerroKin BioSciences for $100 million up front and $225 million in milestones as a "strategic step in building its haematology business". FerroKin brings a "differentiated" development candidate to Shire's portfolio, the Phase II-stage iron chelator FBS0701, it added.